Lixte Bio Shares Jump on LB-100 Trial
By Dean Seal
Shares of Lixte Biotechnologies jumped after the company said it will launch a trial to assess whether its drug LB-100 can aid immunotherapy in the treatment of ovarian clear cell carcinoma.
The stock was up 11% at $1.95 in early trading. Shares have fallen 62% since the start of the year.
The Pasadena, Calif.-based biotechnology company said the Phase 1b collaborative clinical trial will assess whether adding LB-100 to GSK's programmed death receptor-1 blocking monoclonal antibody, dostarlimab, can enhance its effectiveness in treating ovarian clear cell carcinoma.
GSK will provide dostarlimab and financial support for the clinical trial.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
September 20, 2023 10:05 ET (14:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software